Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
MGD |
|
|
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
β-Catenin is essential for many developmental processes and has been implicated in tumorigenesis in many tissues, including prostate cancer.
|
23300485 |
2013 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
β‑catenin nuclear translocation induced by HIF‑1α overexpression leads to the radioresistance of prostate cancer.
|
29658569 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
β-catenin has also been reported to form complex with AR and thus augment AR signaling in PCa.
|
31027362 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Beta-catenin mutations in human prostate cancer.
|
9635571 |
1998 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A marked difference was observed in the expression and distribution of β‑catenin in different prostate cancer cell lines.
|
28035382 |
2017 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Abnormal expression of Wnt5a and beta-catenin was observed in 27 (28%) and 49 (50%) of 98 prostate cancer cases, respectively, by immunohistochemical analyses.
|
20101234 |
2010 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Alpha-methylacyl-CoA racemase (AMACR) is highly overexpressed in prostate cancer (PCa) and its transcriptional regulators include various transcription factors and CTNNB1/β-catenin.
|
28741117 |
2017 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although evidence of abnormal activation of the Wnt pathway in prostate cancer has been demonstrated by several groups, APC and beta-catenin mutations are infrequent.
|
18514389 |
2009 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although the cellular origin of CaP in patients cannot be easily determined at present, the results imply that β-catenin inhibition is a potential therapeutic option for a subset of patients with basal-derived CaP.
|
25712462 |
2015 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
APC or CTNNB1 mutations in colorectal, endometrial and prostate cancers activate the WNT/β-catenin signaling cascade.
|
28731148 |
2017 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
APC, RAR-beta, PTGS2, GSTP1, EDNRB, and CTNNB1 (83%, 71%, 65%, 33%, 14%, 9%, respectively) were methylated in pCA but rarely or not methylated in BPH.
|
16956712 |
2007 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers.
|
11921277 |
2002 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
As a translational research tool, OCP identified adaptive CTNNB1 amplifications/mutations in treated prostate cancers.
|
25925381 |
2015 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Because activating mutations in the beta-catenin gene are rare in prostate cancer, we have looked for altered expression of other components of the Wnt signaling pathway in prostate cancer cells.
|
15520198 |
2004 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Because mutations in adenomatous polyposis coli, β-catenin and other components of the destruction complex are generally rare in PCas, other mechanisms of aberrant Wnt signaling activation have been speculated.
|
25893287 |
2016 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because we had demonstrated that PrKD1 is the only known kinase to phosphorylate threonine 120 (T120) of beta-catenin in prostate cancer resulting in increased nuclear beta-catenin, we explored the role of beta-catenin in gene regulation of <i>PrKD1</i>.
|
29108267 |
2017 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
CLCA2 promoted PCa cell adhesion inhibiting epithelial-mesenchymal transition (EMT) and activating CTNNB1 together with epithelial marker (CDH1) induction, and mesenchymal markers (SNAI2 and TWIST1) repression.
|
29536528 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells.
|
26509262 |
2015 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Downregulation of RORα1 and upregulation of Wnt/β-catenin target genes were correlated in prostate cancer patients.
|
30987323 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression rates driven by osteoblast- specific fragments from the collagen1A1-promoter, the human Osteocalcin-promoter, the bone-sialoprotein promoter and the beta-catenin promoter depending on vitamin supplementation were analysed in five OS cell lines, in normal lung fibroblasts and in a non-osteoblastic prostate cancer cell line (LNCaP) by dual luciferase assays.
|
15375610 |
2004 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, beta-catenin protein expression and intracellular localization were evaluated on 212 patients [122 localized PrCa and 90 hormone-refractory (HRPC) PrCa specimens by immunohistochemistry].
|
12738737 |
2003 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, we demonstrated that rottlerin was able to suppress the expression of cyclin D1 and survivin, two targets of both Wnt/β-catenin and mTORC1 signaling, in prostate and breast cancer cells, and displayed remarkable anticancer activity with IC(50) values between 0.7 and 1.7 μM for prostate cancer PC-3 and DU145 cells and breast cancer MDA-MB-231 and T-47D cells.
|
24607787 |
2014 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
For the first time we provide experimental evidence that the C-terminus of p53 plays an important role in the down-regulation of beta-catenin-mediated TCF-signalling in PCa-cell lines possibly via p53 transrepressional function.
|
17929268 |
2007 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, increased membranous sFRP4 expression was associated with increased membranous beta-catenin expression (P = 0.02) in a cohort of 224 localized human androgen-dependent prostate cancers.
|
17476687 |
2007 |